enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Cigna to help health plans limit costs amid boom in weight ...

   www.aol.com/news/cigna-aims-help-health-plans...

   Cigna Group said on Thursday its pharmacy benefit management unit had launched a program aiming to cap annual cost increases for health insurance providers and employers from new weight-loss drugs ...

3. New Weight Loss Drug Zepbound Cost Break Down: With and ... - AOL

   www.aol.com/weight-loss-drug-zepbound-cost...

   Zepbound, which is the brand name for tirzepatide, targets glucagon-like peptide 1 agonists which stimulate the body to produce more insulin when blood sugars start to rise, along with something ...

4. The Zepbound Shortage Is Over — Here's What to Expect ... - AOL

   www.aol.com/zepbound-shortage-over-heres-expect...

   Eli Lilly’s weight loss drug Zepbound is no longer in short supply, the FDA said, worrying patients who use cheaper, off-brand versions of the drug.. On Thursday, Dec. 19, the U.S. Food and Drug ...

5. Eli Lilly to sell Zepbound directly to consumers without ...

   www.aol.com/eli-lilly-sell-zepbound-directly...

   With insurance coverage, Zepbound can cost as low as $25 per month, but without coverage, the medication can cost more than $1,000 per month. Consumers who purchase Zepbound through LillyDirect ...

6. Cigna - Wikipedia

   en.wikipedia.org/wiki/Cigna

   The Cigna Group is an American multinational for-profit managed healthcare and insurance company based in Bloomfield, Connecticut. [2] [3] Its insurance subsidiaries are major providers of medical, dental, disability, life and accident insurance and related products and services, the majority of which are offered through employers and other groups (e.g., governmental and non-governmental ...

7. Tirzepatide - Wikipedia

   en.wikipedia.org/wiki/Tirzepatide

   Neither the patient nor the healthcare provider knew which treatment was being given until after the trials were completed. [42] Treatment was given for 40 weeks. [ 42 ] In the other three trials (NCT3987919, NCT03882970, and NCT03730662), participants were randomly assigned to receive either tirzepatide or another antidiabetic medication, and ...

8. FDA approves weight-loss drug Zepbound for obstructive ... - AOL

   www.aol.com/news/fda-approves-weight-loss-drug...

   Without insurance coverage, Zepbound costs $1,060 per month, but Lilly offers discounts, coupons and a lower-priced version that comes in a vial that patients use a syringe to inject instead of an ...

9. Aetna Health Inc. v. Davila - Wikipedia

   en.wikipedia.org/wiki/Aetna_Health_Inc._v._Davila

   The Court ruled that Mr. Davila's and Ms. Calad's (the Respondents') state of Texas Causes of Action, both involving Utilization Review decisions by Managed Care entities (in this case CIGNA and Aetna) that were alleged to adversely affect patient care, where in both cases Utilization review decisions contradicted the advice of the Respondents ...